https://cn.immuneonco.com/news/gsdynamics/623.html
ImmuneOnco's Amulirafusp Alfa (IMM0306) Receives FDA IND Clearance Phase Ib/II Clinical Trial in...
This milestone represents a key step forward in the global clinical development of IMM0306 across autoimmune diseases, bringing a potential breakthrough...
amulirafusp alfaphase ibclinical trialreceivesfda